Abstract. Tumor suppressor genes (TSGs) are frequently involved in the pathogenesis of hepatocellular carcinoma (HCC). The epigenetic and genetic alterations of a novel TSG-protocadherin 9 (PCDH9) and its functions in the pathogenesis of HCC were investigated. The methylation status of the PCDH9 promoter was quantitatively analyzed, and the PCDH9 expression was analyzed in HCC cell lines treated with 5-azacytidine. The effects of PCDH9 re-expression and knockdown on growth, proliferation and tumorigenic potential were determined. The results indicated that expression of PCDH9 mRNA was restored in hypermethylation HCC cells following treatment with the DNA de-methylation reagent 5'-Aza. Methylation of the PCDH9 promoter was observed in 22% primary HCC tissues (24/111 tumors). Among the primary HCC cases, the methylated PCDH9 appeared to be associated with a larger tumor size (≥5 cm; P=0.0139) and a more pronounced intrahepatic dissemination (P=0.0312). In addition, it was observed that restored PCDH9 expression could inhibit tumor cell proliferation and xenograft tumor formation. Furthermore, restored PCDH9 expression could inhibit cell proliferation of HCC cell lines via inducing cell cycle arrest at G0/G1 phase. Thus, it is suggested that PCDH9 may act as a novel tumor suppressor candidate gene in HCC pathogenesis.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and ranks the third in global cancer mortality rates (1). HCC mortality increases with tumor invasiveness, despite advances in detection, treatment and surveillance strategies. Novel molecular biomarkers are required in order to assist in outcome prediction and in the identification of high-risk patients who would benefit from aggressive postoperative therapy.

Genetic alterations including point mutations, chromosomal deletion/amplification, or epigenetic changes including promoter hypermethylation and genome wide hypomethylation may be implicated in this process (2,3). At present, published studies have reported the loss of heterozygosity (LOH) are frequently detected in HCC and potential tumor-suppressor genes on chromosomes 1p, 4q, 5q, 8p, 8q, 10q, 11p, 13q, 16q and 22q have been suggested (4-8). A previous study implies that allelic losses on 13q may bring about a more aggressive tumor behavior, and inactivation of these genes via allelic losses likely enhances tumor progression in HCC (9).

The cadherin superfamily, a large family of transmembrane or membrane-associated glycoprotein, serve an essential role in regulation of organ and tissue development during embryogenesis and formation of stable cell-cell junctions and maintenance of normal tissue structure in adult organisms (10,11). Certain cadherins have been identified to act as tumor suppressor genes (TSGs), including E-cadherin, a classic cadherin member, which was first described among the cadherin protein family as L-CAM in chicken and then defined as a potential suppressor of invasion and metastasis.
in lobular breast carcinoma, and pancreatic and epithelial ovarian cancer (12-14).

The protocadherins (PCDHs) are a group of calcium-dependent adhesion proteins that make up a major subfamily of the cadherin superfamily (15). They are abundantly expressed in the central nervous system during embryonic development and during adulthood (16). In contrast to classical cadherins that potentiate strong cell-cell adhesion through homophilic interactions, the PCDHs appear to have more varied physiological functions (17). Previous studies have suggested that PCDHs (PCDH8, PCDH10, PCDH17 and PCDH20) can function as candidate TSGs in a variety of tumor types (18-21). Epigenetic modifications, particularly DNA CpG methylation, serve a key role in the silencing/inactivation of these TSGs (22,23). The PCDH9 gene has been mapped to 13q21.32 in humans and it encodes a protein that is expressed in a broader variety of tissue types (15). Previous studies have demonstrated that PCDH9 expression was downregulated in non-nodal mantle cell lymphoma and glioblastoma (24,25) as a result of gene copy number alterations, and that exogenous expression of PCDH9 could inhibit cancer cell migration. However, whether this gene contributes to HCC tumorigenesis and metastasis remains unknown.

A 2-Mb array-based comparative genomic hybridization (aCGH) analysis was performed, which identified deletions in chromosome 13q21 (the region to which the PCDH9 gene maps) in 24% (6/25) of tumor specimens tested (26). This frequent deletion of PCDH9 in HCC has prompted the investigation of whether it may act as a potential TSG in HCC pathogenesis using in vitro and in vivo based assay protocols. In the current study, the inactivation of PCDH9 in HCC and its functions in the development of HCC were investigated.

Materials and methods

Liver cancer cell lines and HCC tissues. Human liver cancer cell lines (SNU-449, SNU-182, Huh-7, SNU-387, SK-HEP-1, SMMC-7721, PLC/PRF/5 and Hep3B) were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were maintained in RPMI 1640 or Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Shanghai, China).

A total of 111 patients with HCC who underwent surgery at the Henan Oncology Hospital (Zhengzhou, China) between 2009 and 2013 were enrolled in the present study. Disease-free liver tissues (n=12) were obtained from liver donors in the same hospital. The present study was approved by the Ethics Committee of Peking University Health Science Center (Beijing, China). Written informed consent was obtained from all patients.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and quantification methylation assay. RT-qPCR and quantification methylation assay were performed as described previously (27). The primers used for this methylation status assay are listed in Table I.

Plasmid constructions. The full-length PCDH9 cDNA with a His-tag at its C-terminal was cloned into the pIREs2-EGFP expression vector (Clontech Laboratories, Inc., Mountainview, CA, USA). The pAAV-U6 vector (Cell Biolabs, Inc. San Diego, CA, USA) encodes two effective shRNA (shRNA1 and shRNA2) against PCDH9. Oligonucleotides of the two shRNAs are presented in Table I.

MTT assay. Cell viability was measured using the 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay as described previously (28).

Soft agar growth and in-vivo tumorigenicity assay in nude mice. The anchorage-independent growth capability of cells was measured as described previously (28). The in vivo tumorigenic potential of cells was investigated in 6-week-old male nude mice (weight, ~20 g; n=6). Nude mice were purchased from the Department of Laboratory Animal Science in Peking University Health Science Center (Haidian, Beijing) and housed in the same place. Mice were maintained in specific pathogen-free rooms, using a microisolator (filter bonneted) pressurized, individually ventilated cages. The animals were kept in an animal room under SPF conditions at a room temperature of 22±1°C, with 55±10% relative humidity. Food and water made freely available to the mice. Sterilized or disinfected bedding and cages were used, as was anything that came into contact with the mice. 6-week-old male nude mice received subcutaneous injections of 5×10⁶ HCC cells (SNU-449, Hep3B or PLC/PRF/5) in either side of the posterior flank in a volume of 100 µl. Tumor formation was monitored every week over a 6 week period (SNU449) or 5 weeks period (Hep3B or PLC/PRF/5), depended on the size of the tumor. The tumor volume was calculated by the formula: volume=0.5 x length x width² (in mm), the maximum tumor size was 616.1 mm³ (29).

Western blot analysis. Western blot analysis was performed as described previously (28). Cells were lysed in RIPA buffer (RO278; Sigma-Aldrich, Merck Millipore, Germany) and the total cellular protein was resolved on denaturing polyacrylamide gels, transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and blotted with primary antibodies. The dilution and catalog no. of primary antibodies used in the present study are listed in Table II. Protein-antibody complexes were visualized using secondary antibodies conjugated with Cy5.5 (catalog. no. RPN998; 1:10,000 dilution; GE Healthcare Life Sciences) and visualized by LI-COR Odyssey IR Imaging System (LI-COR Biosciences, Lincoln, NE, USA).

Statistical analysis. All statistical analyses were performed with SAS 9.1 software (SAS Institute Inc., Cary, NC, USA). The comparison of the patient genome methylation status was analyzed using the Chi-square test, when n<5 Fisher's exact test was used. The significant differences in the cell growth of clones stably overexpressing PCDH9 and clones transfected with control plasmid were determined using paired t-tests. Differences in tumor growth rate were determined as described previously followed by Tukey's post hoc test. All tests were 2-sided statistical analyses and P<0.05 was considered to indicate a statistically significant difference.
Results

Downregulation of PCDH9 expression in HCC tissues.

Downregulation of PCDH9 mRNA was detected in 5 (Huh-7, SMMC-7721, SK-HEP-1, SNU-182 and SNU-449) of the 8 HCC-derived cell lines, compared with the level observed in controls obtained from normal liver tissues (Fig. 1A).

DNA methylation and histone deacetylation contributes to the downregulation of PCDH9 expression seen in HCC. In the aCGH assay performed on a subset of the HCC samples, deletions of the chromosomal region (13q21.32) where PCDH9 located was detected in only certain 25% (6 of 25) tumor tissues analyzed (data not shown). Therefore, to investigate if hypermethylation also contributes to PCDH9 downregulation in HCC, the methylation status of the PCDH9 promoter was examined in HCC cell lines and tumor-derived tissue samples. Subsequently, the CpG island in the promoter of PCDH9 was analyzed and the primer was designed to detect methylation status of PCDH9 as presented in Fig. 1B. Amongst the 8 HCC cell lines examined, SMMC-7721 alone exhibited significant PCDH9 promoter hypermethylation and in this case, treatment of cells with the DNA demethylation reagent 5-Aza (5-aza-2’-deoxycytidine) restored PCDH9 gene expression, however similar treatment of HCC-derived cell lines that did not show hypermethylation of the PCDH9 promoter had no effect on PCDH9 expression (Fig. 1C). In addition, it was identified that treatment of cells with the specific histone deacetylase inhibitor trichostatin (TSA), restored PCDH9 gene expression in Huh-7 and SNU-182 cells. While combined treatment of SMMC-7721 cells with TSA and 5-Aza indicated that the expression of PCDH9 was higher than 5-Aza treatment alone (Fig. 1D), these results indicated that methylation and histone deacetylation of the PCDH9 had effects on PCDH9 expression. In addition, 22% of the HCC tumor-derived tissues tested (24/111 paired samples successfully analyzed) indicated higher levels of methylation in the tumor tissue sample compared with that observed in the corresponding adjacent non-tumor tissues and normal liver tissues, however such differences did not reach statistical significance (P>0.05; Fig. 1E). Nevertheless, the level of PCDH9 mRNA in tumor tissues that exhibited hypermethylation was also identified to be significantly lower than that observed in the un-methylation group (P=0.032; Fig. 1F). These data suggest that DNA hypermethylation can also mediate the downregulation of PCDH9 expression observed in HCC.

A further notable result was the significant association of PCDH9 hypermethylation with larger tumor size observed (≥5 cm; P=0.0139) and the more pronounced intrahepatic dissemination (P=0.0312) were identified (Table I).

PCDH9 inhibits tumor cell proliferation and xenograft tumor formation. To further explore the role of PCDH9 in HCC, the HCC-derived cell line SNU-449 that exhibited low levels of endogenous PCDH9 expression was transfected with either a PCDH9 expression constructor or control pIRES2-EGFP

| Table I. Primers used in the current study. |
|---------------------------------------------|
| Primer | Sequence (5’-3’). |
| PCDH9-methy-F1 | CTCCAGGCGCCACACTTCAGCA |
| PCDH9-methy-R1 | GCTGACCGAGGGGACCCAGA |
| PCDH9-LOH-F1 | TACCGTGTGCGTCAGAGCTT |
| PCDH9-LOH-R1 | GTCCAATACGTTGTTAACAACGACCA |
| PCDH9-LOH-F2 | TGTTGCGAAAGTCCTACAACAGGCA |
| PCDH9-LOH-R2 | TCTCTTGGCTGCAATTTTCTCTCT |
| PCDH9-LOH-F3 | TGGTAACATCAGCTCACAACATC |
| PCDH9-LOH-R3 | CCACACATGGGCAATAAGATGCT |
| PCDH9-LOH-F4 | CAGGCTCCATATGTAAGAAATACAC |
| PCDH9-LOH-R4 | CAGCATTGCAAGGAGTCAAGAGA |
| PCDH9-LOH-R5 | AGGGTGGGCTATGATGATGAA |
| PCDH9-F | TCCCAACTCTGATGCGCTTTGG |
| PCDH9-R | GGCTCTTGGTGAGGTGGAGCC |
| shRNA1-1 | GATCCGCCGCGATATGACAA |
| shRNA1-2 | CAATATTTTCAAGAGA |
| shRNA1-3 | ATATGGTGGTGTGATATCACGCTTTTA |
| shRNA1-4 | ATATCTGGTGTGATATACCGCGGG |
| shRNA2-1 | AGCTTTAAAAACGGTTATAGACAA |
| shRNA2-2 | CCAATATTTTCAAGAGA |
| shRNA2-3 | GTACCCCCCAAGGTTACATATA |
| shRNA2-4 | TCTATTGCAAGAGA |

PCDH9, protocadherin 9; F, forward; R, reverse; LOH, loss of heterozygosity; sh, short hairpin.

PCDH9, protocadherin 9; F, forward; R, reverse; LOH, loss of heterozygosity; sh, short hairpin.

| Table II. Antibodies used in western blotting. |
|-----------------------------------------------|
| Antibody | Company (catalog number) | Dilution |
| Anti-α-tubulin | MBL (JM-3708-100) | 1:3,000 |
| Anti-GAPDH | MBL (M171-3) | 1:3,000 |
| Anti-PCDH9 | Santa Cruz (sc-84564) | 1:200 |
| Anti-his | MBL (D291-3) | 1:2,000 |
| Anti-p21 (Natt/Cip) | MBL (K0081-3) | 1:500 |
| Anti-p27 (Kip) | Cell Signaling (#3698) | 1:500 |
| Anti-cyclin D1 | MBL (K0062-3) | 1:500 |
| Anti-cyclin E | MBL (K0172-3) | 1:500 |

MBL, MBL International, Woburn, MA, USA; PCDH9, protocadherin 9; Santa Cruz, Santa Cruz Biotechnology, Inc., Dallas, TX, USA; His, histidine; Cell Signaling, Cell Signaling Technology, Inc., Danvers, MA, USA.

Molecular Medicine Reports 16: 4475-4482, 2017
LV et al.: PCDH9 INDUCES ARREST AT G₀/G₁ PHASE AND IS FREQUENTLY METHYLATED IN HCC

Figure 1. Downregulation of PCDH9 in HCC cell lines and tumor tissues. (A) Expression of PCDH9 in 8 HCC cell lines and 12 control normal liver tissues (mean ± standard deviation; n=3). (B) CpG island in the promoter of PCDH9 and methylation primer design of PCDH9. (C) The expression of PCDH9 in 8 HCC cells treated by 5-Aza (mean ± standard deviation; n=3). The PCDH9 expression level in mock treated cells was set at an arbitrary value of 1 to facilitate comparison. (D) The expression of PCDH9 in 8 HCC cells treated by TSA (mean ± standard deviation; n=3). The PCDH9 expression level in mock treated cells was set at an arbitrary value of 1 to facilitate comparison. (E) The methylation intensity of PCDH9 in normal liver, non-tumor and tumor tissues. Significant differences were determined using Student’s t-test. (F) The expression of PCDH9 in hypermethylation group and unmethylation group. The lines in the grouped column scatter indicate the mean ± standard deviation. ‘MI≥10%’: Hypermethylation group; ‘MI<10%’: Unmethylation group. Significant differences were determined using Student’s t-test. PCDH9, protocadherin 9; HCC, hepatocellular carcinoma; 5-Aza, 5-aza-2-deoxycytidine; TSA, trichostatin; MI, methylation intensity.

Separately, two HCC cell lines (Hep3B and PLC/PRF/5) that exhibited high levels of endogenous PCDH9 expression were transfected with either PCDH9 knockdown (shRNA1 and shRNA2) or control pAAV-U6 plasmids. Following G418 selection, stable clones of SNU-449 cells in which the expression of PCDH9 had been increased were obtained, in addition to stable clones of Hep3B and PLC/PRF/5 in which endogenous PCDH9 expression had been suppressed. The overexpression of PCDH9 and suppression of endogenous PCDH9 expression was confirmed by western blot analysis (Fig. 2A).

The ability of PCDH9 expression to affect cell proliferation was analyzed in these over- and underexpressing cell clones using an MTT assay. This indicated that the growth of SNU-449 cells overexpressing ectopic PCDH9 was significantly suppressed compared with that observed in clones transfected with control plasmid (P=0.0125; Fig. 2B). By contrast, the use of shRNA1 and shRNA2 to efficiently knockdown endogenous PCDH9 expression significantly enhanced cellular proliferation in Hep3B-(P=0.0107 and P=0.0110; Fig. 2B) and PLC/PRF/5 (P=0.0118 and P=0.0120; Fig. 2B)-derived clones.

A second in vitro assay measuring the ability of these clones to form colonies in soft agar was also undertaken as an indicator of their tumorigenic potential. This indicated that the SNU-449-derived clones had decreased colony-forming efficiency compared with mock-transfected controls (P=0.0101; Fig. 2C). By contrast the PCDH9 knockdown in the Hep3B derived clones induced the cells to form much larger colonies.
in soft agar than that observed in controls (P=0.0025 and P=0.0086, respectively; Fig. 2C). Similar results were also obtained with the PLC/PRF/5-derived knockdown clones (P=0.0004 and P=0.0011, respectively; Fig. 2C).

To investigate tumorigenic potential in vivo, a tumor formation assay was conducted in nude mice. A total of 5 weeks after injection, significant differences in average tumor size were observed; 545.8±131.9 mm$^3$ in mice injected with control SNU-449 cells and only 171.5±92.1 mm$^3$ in mice injected with SNU-449 expressing ectopic PCDH9 (P=0.0151; Fig. 2D and E). This is contrasted with the five week post-injection image observed for Hep3B clones in which PCDH9 expression had been knocked-down following transfection with plasmids expressing either shRNA1 or shRNA2, an average 5 week post injection tumor size of 220.3±60.8 mm$^3$ in mice injected with control clones and 372.7±49.8 mm$^3$ for clones expressing shRNA1 (P=0.0364), and 309.2±38.6 mm$^3$ for clones expressing shRNA2 (P=0.0401; Fig. 2D and E). PCDH9-knockdown with either shRNA1 or shRNA2 also resulted in PLC/PRF/5 clones which had significantly increased tumor formation when injected into nude mice compared with that produced following injection of the control counterpart (P=0.0401 and P=0.0456; Fig. 2D and E).
PCDH9 inhibits cell proliferation of HCC cell lines via inducing cell cycle arrest at G₀/G₁ phase. PCDH9 was also identified to have effects on HCC cells in which there was ectopic overexpression or knockdown of the protein PCDH9. Flow cytometry indicated that in SNU-449 cells, PCDH9 overexpression blocked G₁/S transmission with the percentage of cells in G₁ phase increasing from >55% to ~71%, whilst the percentage in S phase decreased from 29 to 16% (Fig. 3A). By contrast, in Hep3B cells, PCDH9 shRNA1 or shRNA2 decreased G₀/G₁ phase from ~55 to 48% or 50%, respectively, whilst the percentage in S phase increased from ~22 to 29% or 28%, respectively (Fig. 3A). Similarly, in PLC/PRF/5 cells, PCDH9 shRNA1 or shRNA2 decreased G₀/G₁ phase from ~60 to 51% or 54%, respectively, whilst the
percentage in S phase increased from ~20 to 27% or 26%, respectively (Fig. 3A).

The expression of the cell cycle progression regulators cyclin D1, cyclin E, p21<sup>Waf1/Cip1</sup> and p27<sup>Kip1</sup> were also monitored using a western blot assay. Ectopic expression of PCDH9 in SNU-449 cells significantly increased the levels of p21<sup>Waf1/Cip1</sup> and p27<sup>Kip1</sup>, however suppressed cyclin E expression and the protein level of cyclin D1 remained unchanged (Fig. 3B). In addition, in Hep3B and PLC/PRF/5 cells, PCDH9 shRNA1 or shRNA2 decreased the protein levels of p21<sup>Waf1/Cip1</sup> and p27<sup>Kip1</sup>, while increasing the cyclin E expression, and the protein level of cyclin D1 was unchanged (Fig. 3C). These results suggested that it may induce G<sub>1</sub> phase arrest by regulating the expression of cell cycle regulators.

Discussion

Previously, the downregulation of PCDH9 was observed in primary HCC, and PCDH9 was identified to inhibit epithelial-mesenchymal transition and cell migration through activating GSK-3β (30). However, the mechanism remains unclear. The current study aimed to investigate the mechanism and the function of the PCDH9 in HCC cells.

The pathogenesis and development of HCC is a multi-step process involving genetic and epigenetic alterations. Epigenetic alterations (such as DNA methylation and histone deacetylation) are clinically notable because they may be able to reverse such changes and restore gene function. Therefore, epigenetic markers could be clinical indicators for the detection, outcome prediction and treatment of HCC. The frequent LOH of PCDH9 gene identified in previous aCGH data implies that chromosomal deletion accounts for the downregulation of PCDH9 in a significant fraction of HCC cases (13). Epigenetic alterations (such as DNA methylation and histone-modification maps) support the role of epigenetic events in cancer. The present study was supported by the National S & T Major Project for Infectious Diseases (grant nos. 2012ZX10004-904 and 2012ZX10002-007) and the Leading Academic Discipline Project of Beijing and the 111 Project (grant no. B07001) and Natural Science Foundation of Henan Province (grant no. 162300410289).

Acknowledgements

The authors would like to thank Dr Ling Zhang and Professor Quanjun Lv for their help in establishing the HCC tissue specimen database. The present study was supported by the National S & T Major Project for Infectious Diseases (grant nos. 2012ZX10004-904 and 2012ZX10002-007) and the Leading Academic Discipline Project of Beijing and the 111 Project (grant no. B07001) and Natural Science Foundation of Henan Province (grant no. 162300410289).

References

1. Kew M: Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 58: 273-277, 2010.
2. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.
3. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
4. Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T and Nakamura Y: Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity on chromosome 13q occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 13: 163-167, 1995.
5. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohoshi S, Hu SX, Benedict WF and Sekiya T: Deletions of chromosome 13q, mutations in Retinoblastoma 1 and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 54: 4177-4182, 1994.
6. Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T and Nakamura Y: Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 72: 383-385, 1995.
7. Zhu GN, Zuo L, Zhou Q, Zhang SM, Zhuo HQ, Gai SY and Wang Y: Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. World J Gastroenterol 10: 1975-1978, 2004.
8. Wang HP and Rogler CE: Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. CytoGenet Cell Genet 48: 72-78, 1988.
9. Wong CM, Lee JM, Lau TC, Fan ST and Ng IO: Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 8: 2266-2272, 2002.
10. Nollet F, Kools P and Van Roy F: Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol 290: 551-572, 2000.
11. Angst BD, Marcozzi C and Magee AJ: The cadherin superfamily: Diversity in form and function. J Cell Sci 114: 629-641, 2001.
12. Nilles LA, Parry D, Powers EE, Angst BD, Wagner RM and Green KJ: Structural analysis and expression of human desmoglein: A cadherin-like component of the desmosome. J Cell Sci 99: 809-821, 1991.

13. Rakha E, Abd El Rehim D, Pinder S, Lewis S and Ellis I: E-cadherin expression in invasive non-small-cell lung cancer: a candidate tumor suppressor PCDH20 by epigenetic mechanism. Histopathology 46: 685-693, 2005.

14. Sundfeldt K, Pontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brännström M, Janson PO, Enerback S and Hedin L: E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74: 275-280, 1997.

15. Frank M and Kemler R: Protocadherins. Curr Opin Cell Biol 14: 557-562, 2002.

16. Sano K, Tanihara H, Heimark RL, Obata S, Davidson M, St John T, Taketani S and Suzuki S: Protocadherins: A large family of cadherin-related molecules in central nervous system. EMBO J 12: 2249-2256, 1993.

17. Kim SY, Yasuda S, Tanaka H, Yamagata K and Kim H: Non-clustered protocadherin. Cell Adh Migr 5: 97-105, 2011.

18. Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27: 4657-4665, 2008.

19. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136: 640-51.e1, 2009.

20. Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, Muramatsu T, Shimada Y, Kawano T and Inazawa J: Frequent silencing of protocadherin 17, a candidate tumor suppressor for esophageal squamous cell carcinoma. Carcinogenesis 31: 1027-1036, 2010.

21. Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S and Inazawa J: Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66: 4617-4626, 2006.

22. Fuks F: DNA methylation and histone modifications: Teaming up to silence genes. Curr Opin Genet Dev 15: 490-495, 2005.

23. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.

24. Wang C, Yu G, Liu J, Wang J, Zhang Y, Zhang X, Zhou Z and Huang Z: Downregulation of PCDH9 predicts prognosis for patients with glioma. J Clin Neurosci 19: 541-545, 2012.

25. de Tayrac M, Etchevery A, Aubry M, Saikali S, Hamlat A, Quillien V, Le Treut A, Galibert MD and Mosser J: Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 48: 55-68, 2009.

26. Jiang S, Yang Z, Li W, Li X, Wang Y, Zhang J, Xu C, Chen PJ, Hou J, McCrae MA, et al: Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One 7: e40363, 2012.

27. Wang Y, Cheng J, Xu C, Liu S, Jiang S, Xu Q, Chen X, Zhuang H and Lu F: Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int 32: 420-428, 2012.

28. Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA and Zhuang H: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 118: 2431-2442, 2012.

29. Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA and Zhuang H: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 118: 2431-2442, 2012.

30. Zhu P, Lv J, Yang Z, Guo L, Zhang L, Li M, Han W, Chen X, Zhuang H and Lu F: Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochem Biophys Res Commun 452: 567-574, 2014.